erlotinib hydrochloride has been researched along with phenobarbital in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (phenobarbital) | Trials (phenobarbital) | Recent Studies (post-2010) (phenobarbital) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 18,336 | 619 | 1,117 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, S; Gerard, MA; Henderson, CJ; Jimenez, LA; McMahon, M; Moggs, J; Terranova, R; Vitobello, A; Wolf, CR | 1 |
1 other study(ies) available for erlotinib hydrochloride and phenobarbital
| Article | Year |
|---|---|
Constitutive androstane receptor 1 is constitutively bound to chromatin and 'primed' for transactivation in hepatocytes.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromatin; Constitutive Androstane Receptor; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocytes; Humans; Mice; Mice, Inbred C57BL; Phenobarbital; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Transcriptional Activation | 2019 |